Skip to main content
Clinical Trials/NCT02606058
NCT02606058CompletedNot Applicable

A Randomised Two Arm Open Label Controlled Trial Comparing Standard Immediate Cord Clamping Versus Deferring Cord Clamping for 60 Seconds or More in Babies Born Less Than 30 Weeks of Gestation to Determine Which Cord Clamping Method Results in Improved Survival and Less Disability.

University of Sydney26 sites in 7 countries1,637 target enrollmentStarted: September 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
1,637
Locations
26
Primary Endpoint
Death and/or major morbidity at 36 weeks post menstrual age

Study Overview

Brief Summary

To establish if placental transfusion, using deferred cord clamping for 60 seconds or more while holding the baby at or below the level of the placenta, will improve survival without disability compared with standard early cord clamping in preterm babies less than 30 weeks of gestation.

Detailed Description

Most preterm babies have the umbilical cord clamped within 10 seconds of birth. Placental transfusion is a simple way of giving the baby extra blood at birth by delaying the clamping of the umbilical cord by 60 seconds or more. There is promising evidence from randomised trials that placental transfusion in babies less than 37 weeks of pregnancy may improve their blood pressure, reduce the number of blood transfusions needed and decrease bleeding into the brain, bowel disease and infection. However, we not know if babies born before 30 weeks of pregnancy benefit or if placental transfusion increases or decreases death or childhood disability. Despite this uncertainty more doctors are recommending that all very preterm babies are given a placental transfusion at birth. It is important to find out if placental transfusion does more good than harm, before it becomes even more widely used.

The Australian Placental Transfusion Study will enrol at least 1600 women who will give birth to babies born less than 30 weeks of gestation. These participants will be randomly assigned to either standard treatment where the umbilical cord is clamped within 10 seconds of birth or a second method where the umbilical cord will be clamped after waiting for 60 seconds or more at birth while the baby is being held below the level of the placenta. The main research question is whether placental transfusion reduces death and disability when the baby is discharged from hospital and into childhood.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Participant)

Eligibility Criteria

Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Women who have a reasonable chance of delivering less than 30 weeks of gestation. Informed consent has been received from the parent or guardian.

Exclusion Criteria

  • •No indication or contraindication to placental transfusion, in the view of mother or baby.

Arms & Interventions

Early cord clamping (Control Arm)

No Intervention

Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.

Deferred cord clamping

Experimental

Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.

Intervention: Deferred cord clamping (Procedure)

Outcomes

Primary Outcomes

Death and/or major morbidity at 36 weeks post menstrual age

Time Frame: 36 weeks post menstrual age

Composite death and/or major morbidity at 36 completed weeks post menstrual age. Morbidity is defined by one or more of the following: brain injury on ultrasound, severe retinopathy, necrotising enterocolitis, late onset sepsis.

Secondary Outcomes

  • IVH (all grades) seen on ultrasound(36 completed weeks post menstrual age)
  • IVH (Grades 3 & 4) seen on ultrasound(36 completed weeks post menstrual age)
  • Incidence of death or major disability(Up to 3 years corrected age)
  • Incidence of death or brain injury on ultrasound(36 completed weeks post menstrual age)
  • Incidence of major morbidity(36 completed weeks post menstrual age)
  • Major disability defined as cerebral palsy with an inability to walk unassisted, severe visual loss, deafness, major problems with language or speech, or a score indicative of developmental delay on Ages and Stages Questionnaire.(Up to 3 years corrected age)
  • Brain injury on ultrasound(36 completed weeks post menstrual age)
  • Incidence of death(36 completed weeks post menstrual age)
  • IVH (Grade 4) seen on ultrasound(36 completed weeks post menstrual age)
  • Severe retinopathy warranting treatment or Stage 4 retinopathy according to the Australian and New Zealand Neonatal Network (ANZNN) definitions(36 completed weeks post menstrual age)
  • Necrotizing enterocolitis with the following signs: at least 1 systemic sign, profile consistent with definite NEC, warranted treatment for NEC.(36 completed weeks post menstrual age)
  • Patent ductus arteriosis requiring treatment (documented in medical records)(36 completed weeks post menstrual age)
  • Chronic lung disease, defined as receiving supplemental oxygen or any form of assisted ventilation at 36 completed weeks post menstrual age for 4 consecutive hours in a 24 hour period(36 completed weeks post menstrual age)
  • Death up to 3 years corrected age(Up to 3 years corrected age)
  • Late onset sepsis, defined as a clinical picture consistent with sepsis, and either a positive culture of blood and/or CSF, or a positive urine culture by sterile collection, and at least 5 days of antibiotic treatment.(36 completed weeks post menstrual age)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (26)

Loading locations...

Similar Trials